Authors
Emma R Lee, Jacqueline Day, Carla Osiowy, Vanessa Tran, Rachel Ha, Carmen Charlton, Derek Stein, Josh Titus, Christopher F Lowe, Nancy Matic, Todd F Hatchette, Donald G Murphy, Carla S Coffin
Published in
Liver international : official journal of the International Association for the Study of the Liver. Volume 46. Issue 12.
Abstract
CASL/AMMI 2025 guidelines recommend reflex anti-HDV testing for all hepatitis B surface antigen (HBsAg)-positive individuals, replacing risk-based screening, yet Canadian data on HDV testing and detection remain limited. In Canada, only Quebec offers anti-HDV testing; other regions refer samples to the National Microbiology Laboratory (NML), where HDV RNA confirmation is centralised. We assessed HDV testing volume, seroprevalence, RNA positivity, and genotypes in referred samples and randomly selected archived HBsAg-positive samples.
Anti-HDV results from Quebec and the NML from August 2022 to July 2024 were analysed and compared with a 2012-2019 national survey. To complement referral-based surveillance, 3386 randomly selected archived HBsAg-positive samples from five provinces were tested. Seropositive samples underwent HDV RNA testing and genotyping at NML.
Among 8401 unique referred samples, 271 (3.2%; 95% CI, 2.9-3.6) were anti-HDV positive, of which 117 (43.2%; 95% CI, 37.4-49.1) were HDV RNA positive. Compared with 2012-2019, annual testing volume increased fourfold (1011 to 4201 tests/year), while annual detection increased from 48 to 136 anti-HDV-positive individuals and from 31 to 59 HDV RNA-positive individuals. Among archived samples, 67/3386 (2.0%; 95% CI, 1.6-2.5) were anti-HDV positive, and 14/67 (20.9%; 95% CI, 12.9-32.1) were RNA positive. Genotypes 1, 2, 5, 7, and 8 were detected.
Increased HDV testing in Canada was associated with greater detection of anti-HDV-positive and HDV RNA-positive individuals despite lower positivity rates. HDV RNA detection and multiple genotypes in archived HBsAg-positive samples support universal reflex anti-HDV testing, with RNA confirmation, harmonised reporting, and integrated HBV/HDV surveillance.
PMID:
43059085
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0